Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Brain metabolic dysfunction at the core of Alzheimer's disease 2013-12-28
  2. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease 2001-09-01

Studies

2 studies carry this tag.

Date range

2001 to 2013

Top journals

  • Biochemical pharmacology 1
  • The international journal of neuropsychopharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Brain metabolic dysfunction at the core of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochemical pharmacology 2013-12-28 Risk factors

    Growing evidence supports the concept that Alzheimer's disease (AD) is fundamentally a metabolic disease with molecular and biochemical features that correspond with diabetes mellitus and other peripheral insulin resistance disorders.

  2. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. The international journal of neuropsychopharmacology 2001-09-01 Treatments

    In-vivo metabolic measures with positron emission tomography using (18)F-fluorodeoxyglucose (FDG-PET) have demonstrated hypometabolism in temporal, frontal, and hippocampal areas during the early stages of Alzheimer's disease (AD).

All topic tags with their study counts